ViGeneron is dedicated to developing innovative gene therapies to treat ophthalmic diseases with high unmet medical need, as well as partnering with leading biopharmaceutical players in other disease areas. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. The first, vgAAV gene therapy vectorplatform, allows superior transduction efficiency and intravitreal, less invasive treatment administration. The second, REVeRT vector platform, targets diseases caused by mutations in large genes. Privately-owned ViGeneron was founded in 2017 by a seasoned team with in-depth experience in AAV vector technology and clinical ophthalmic gene therapy programs and is located in Munich, Germany.

Biotechnology

Health Care

Therapeutics

ViGeneron

ViGeneron's headquarters in Starnberg, Germany

Caroline Man Xu

Elvir Becirovic

Stylianos Michalakis

Martin Biel

Gang Pei

Siegfried Priglinger

Description

People (1)

Caroline Man Xu

Jobs